← All trials
NCT05562609
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2023
- Primary completion
- Aug 31, 2025
- Completion date
- Sep 30, 2025
- First posted
- Oct 3, 2022
- Last posted
- Nov 16, 2022
- Enrollment
- 30000
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of LondonLead sponsor
- UNITAIDCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.